AstraZeneca plc (LON:AZN) will be releasing its earnings data on Wednesday, July 26th. Analysts expect AstraZeneca plc to post earnings of $0.85 per share for the quarter.

Shares of AstraZeneca plc (LON AZN) opened at 5069.00 on Wednesday. The firm’s 50-day moving average price is GBX 5,259.89 and its 200 day moving average price is GBX 4,769.91. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The company’s market cap is GBX 64.17 billion.

AZN has been the subject of several research reports. Societe Generale restated a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, March 23rd. Liberum Capital restated a “buy” rating and issued a GBX 5,100 ($66.60) price target on shares of AstraZeneca plc in a research note on Tuesday, March 21st. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,500 ($71.82) price target on shares of AstraZeneca plc in a research note on Tuesday, March 21st. Kepler Capital Markets restated a “buy” rating and issued a GBX 5,000 ($65.29) price target on shares of AstraZeneca plc in a research note on Friday, April 21st. Finally, Morgan Stanley restated a “buy” rating on shares of AstraZeneca plc in a research note on Monday, April 24th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. AstraZeneca plc presently has an average rating of “Hold” and an average target price of GBX 5,251.80 ($68.58).

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (LON:AZN) to Release Earnings on Wednesday” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/19/astrazeneca-plc-lonazn-to-release-earnings-on-wednesday.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.